Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prostatic cancer marker and therapeutic drug thereof

A prostate cancer and prostate technology, applied in the field of tumor biology, can solve the problems that the pathogenesis of prostate cancer is not fully understood and the pathogenesis of prostate cancer is complicated

Active Publication Date: 2021-05-18
SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the pathogenesis of prostate cancer is very complex, so the pathogenesis of the occurrence and progression of prostate cancer is not yet fully understood.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostatic cancer marker and therapeutic drug thereof
  • Prostatic cancer marker and therapeutic drug thereof
  • Prostatic cancer marker and therapeutic drug thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Tissue total RNA extraction

[0040] (1) Before starting the experiment, soak the equipment required for the experiment in 0.1% DEPC water overnight, and dry it in the oven for later use;

[0041] (2) Take about 50 mg of fresh tumor tissue and paracancerous tissue, use ophthalmic scissors to cut the tissue into a pre-cooled mortar, pour liquid nitrogen into it, grind the tissue quickly, and transfer the tissue to In a new RNase-free 1.5ml EP tube;

[0042] (3) Add 1ml of Trizol lysate, let stand at room temperature for 5min, add 200ul of chloroform, vortex for 30s with a vortexer, and place on ice for 10min;

[0043] (4) Put the EP tube into a centrifuge at 4°C and centrifuge at 12000g for 15 minutes. After the end, carefully transfer the supernatant to a new 1.5ml EP tube;

[0044] (5) Add an equal volume of isopropanol and mix well, place on ice for 10 minutes, put the EP tube into a centrifuge at 4°C, centrifuge at 12000g for 10 minutes, and discard the supernatant...

Embodiment 2

[0067] Detection of the expression difference of Lnc-RP5-952N6.1 in prostate cancer cells

[0068] (1) Extract RNA from BPH-1 cells, DU-145 cells, LnCap cells, PC3 cells, and VCaP cells according to the method in Example 1;

[0069] (2) According to the method of Example 1, the expression difference of Lnc-RP5-952N6.1 in BPH-1 cells, DU-145 cells, LnCap cells, PC3 cells, and VCaP cells was detected.

[0070] Among them, the relative expression level of Lnc-RP5-952N6.1 in DU-145 cells was 3.606±0.243;

[0071] The relative expression level of Lnc-RP5-952N6.1 in LnCap cells was 2.613±0.199;

[0072] The relative expression level of Lnc-RP5-952N6.1 in PC3 cells was 2.332±0.452;

[0073] The relative expression level of Lnc-RP5-952N6.1 in VCaP cells was 3.023±0.310;

[0074] The above results indicated that the relative expression of Lnc-RP5-952N6.1 in prostate cancer cells was significantly increased compared with BPH-1 in human prostatic hyperplasia cells, and the expression ...

Embodiment 3

[0076] Design shRNA sh-Lnc-RP5-952N6.1 for Lnc-RP5-952N6.1

[0077] (1) Design shRNA according to the sequence SEQ ID NO.5 of Lnc-RP5-952N6.1, and construct it on the pENTR™ / U6 plasmid, as follows:

[0078] Top Strand:

[0079] 5'-CACCGCGGCTTCCTCTAGAATAAAGCGAACTTTATTCTAGAGGAAGCCGC-3'; SEQ ID NO.6;

[0080] Bottom Strand

[0081] 5'-AAAAGCGGCTTCCTCTAGAATAAAGTTCGCTTTATTCTAGAGGAAGCCGC-3'; SEQ ID NO.7;

[0082] (2) Transfect sh-Lnc-RP5-952N6.1 into DU-145 cells, and detect the inhibitory effect of sh-Lnc-RP5-952N6.1.

[0083] Among them, in DU-145 cells transfected with sh-Lnc-RP5-952N6.1, the relative expression level of Lnc-RP5-952N6.1 was 0.198±0.031, indicating that sh-Lnc-RP5-952N6.1 can effectively inhibit Expression of Lnc-RP5-952N6.1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a prostatic cancer marker and a therapeutic drug thereof, and belongs to the technical field of tumor biology. By detecting the difference of the expression quantity of Lnc-RP5-952N 6.1 in prostatic cancer tissue and para-carcinoma tissue, the result shows that Lnc-RP5-952N 6.1 is highly expressed in the prostatic cancer tissue, the expression difference of Lnc-RP5-952N 6.1 in the prostatic cancer tissue and para-carcinoma tissue has excellent specificity and sensitivity, and therefore Lnc-RP5-952N 6.1 can serve as the marker of prostatic cancer and is used for assisting in diagnosis of prostatic cancer.

Description

technical field [0001] The invention belongs to the technical field of tumor biology, and in particular relates to a prostate cancer marker and a therapeutic drug thereof. Background technique [0002] Prostate cancer is a common urinary system malignancy in elderly men. With the change of diet and lifestyle and the aging of the population, the number of prostate cancer patients is increasing, which seriously threatens the health of middle-aged and elderly men. At the same time, prostate cancer is also showing a younger trend. The early clinical symptoms of prostate cancer patients are not obvious, and the patients are often already at an advanced stage when they see a doctor, thus losing the opportunity for surgical treatment. Therefore, if the progress of prostate cancer can be diagnosed and intervened early, it will help to reduce the harm of prostate cancer to patients and improve the treatment effect of patients. However, the pathogenesis of prostate cancer is very c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/178C12Q2600/158C12Q2600/136A61K45/00A61K31/713A61P35/00A61P35/04
Inventor 侯东省夏志明张亚洲周霞宋琳宗园媛
Owner SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com